Understand the source comparison
Pe-22-28 Comparison: TrkB Agonists and BDNF Mimetics in 2026
Researchers evaluating Pe-22-28 in 2026 typically compare it against other TrkB agonists, alternative BDNF mimetics, and small-molecule neuroplasticity enhancers. The table below summarizes key pharmacological and practical differences based on published 2026
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers evaluating Pe-22-28 in 2026 typically compare it against other TrkB agonists, alternative BDNF mimetics, and small-molecule neuroplasticity enhancers. The table below summarizes key pharmacological and practical differences based on published 2026 research data.
- Pe-22-28
- TrkB agonist (loop 2 mimetic)
- 0.5–2.0 mg/kg SC/IP
- Moderate (2–5% BBB crossing estimated)
- 72 hours at 2–8°C
- Requires daily dosing; limited human data
- Best-in-class stability for BDNF mimetic peptides; selective TrkB activation without p75NTR engagement makes it ideal for neuroplasticity studies
- 7,8-DHF (small molecule)
- TrkB agonist
- 5–10 mg/kg oral
- High (>40% BBB crossing)
- Stable in solution for weeks
- Non-selective; activates other kinases at higher doses
- Oral bioavailability and CNS penetration exceed Pe-22-28, but off-target kinase activity complicates interpretation in mechanism studies
- Full-length BDNF
- Native TrkB and p75NTR ligand
- 1–10 μg intracerebroventricular
- Poor (requires direct CNS injection)
- <10 minutes in plasma
- Cannot be administered systemically; dual receptor binding
- Gold standard for validating TrkB-dependent effects, but impractical for chronic or systemic studies
- NSI-189
- Hippocampal neurogenesis enhancer
- 10–40 mg/kg oral
- Moderate
- Stable
- Mechanism incompletely defined; not selective for TrkB
- Useful for neurogenesis studies but lacks the receptor selectivity needed to isolate TrkB-mediated plasticity
- Dihexa
- HGF/c-Met pathway activator
- 0.5–2.0 mg/kg SC
- High
- 48 hours at 2–8°C
- Potent but works through HGF, not BDNF/TrkB axis
- Complementary to Pe-22-28; combining both may engage multiple neuroplasticity pathways synergistically
- Pe-22-28 occupies a unique position: it delivers TrkB selectivity comparable to full-length BDNF without requiring intracerebroventricular administration, and it maintains stability far beyond what native BDNF offers. The trade-off is moderate CNS penetration. Only 2–5% of systemically administered Pe-22-28 is estimated to cross the blood-brain barrier, compared to 40%+ for small molecules like 7,8-DHF. For researchers prioritizing clean TrkB-specific signaling with minimal off-target kinase activation, Pe-22-28 is the superior choice despite the penetration limitation. For studies requiring maximal CNS exposure or oral dosing convenience, 7,8-DHF or Dihexa may be more appropriate.
- Real Peptides supplies Pe-22-28 synthesized through small-batch solid-phase peptide synthesis with exact amino-acid sequencing, third-party HPLC verification, and ≥98% purity certification. Every batch includes mass spectrometry confirmation of molecular weight and sequence fidelity. Documentation that should be standard but remains inconsistent across the peptide supply industry in 2026.